{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:32:47Z","timestamp":1792215167281,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12072-026-11091-7","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:29:04Z","timestamp":1776788944000},"page":"1127-1137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of first and further decompensation events in advanced chronic liver disease: a multi-centre competing risks analysis"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9137-0204","authenticated-orcid":false,"given":"Angus W.","family":"Jeffrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon A.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Brew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Jeffrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Testro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Chetwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avik","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"3","key":"11091_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","volume":"68","author":"G D\u2019Amico","year":"2018","unstructured":"D\u2019Amico G, Morabito A, D\u2019Amico M, Pasta L, Malizia G, Rebora P, et al. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68(3):563\u2013576. https:\/\/doi.org\/10.1016\/j.jhep.2017.10.020","journal-title":"J Hepatol"},{"key":"11091_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.06.014","author":"G Pennisi","year":"2025","unstructured":"Pennisi G, Di Maria G, Wong VWS, de Ledinghen V, Sebastiani G, Vigan\u00f2 M, et al. Impact of first and further decompensation in patients with compensated ACLD due to MASLD. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.06.014","journal-title":"J Hepatol"},{"key":"11091_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000652","author":"G D\u2019Amico","year":"2023","unstructured":"D\u2019Amico G, Zipprich A, Villanueva C, Sord\u00e0 JA, Morillas RM, Garcovich M, et al. Further decompensation in cirrhosis: results of a large multicenter cohort study supporting Baveno VII statements. Hepatology. 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000652","journal-title":"Hepatology"},{"issue":"6","key":"11091_CR4","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/hep.28824","volume":"64","author":"JG Abraldes","year":"2016","unstructured":"Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the \u201cAnticipate\u201d study. Hepatology. 2016;64(6):2173. https:\/\/doi.org\/10.1002\/hep.28824","journal-title":"Hepatology"},{"key":"11091_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.10.002","author":"AW Jeffrey","year":"2025","unstructured":"Jeffrey AW, Chen J, Chin A, Tsochatzis EA, Majumdar A, Calzadilla-Bertot L, et al. Noninvasive prediction models of first decompensation in compensated advanced chronic liver disease: a meta-analysis. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.10.002. (PubMed PMID: 41076042)","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"11091_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jhep.2024.01.039","volume":"80","author":"F Artru","year":"2024","unstructured":"Artru F, Reiberger T. One - or more - blind spot(s) unveiled in the new definition of decompensated cirrhosis. J Hepatol. 2024;80(4):537\u2013539. https:\/\/doi.org\/10.1016\/j.jhep.2024.01.039. (PubMed PMID: 38340813)","journal-title":"J Hepatol"},{"issue":"4","key":"11091_CR7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII \u2013 renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959\u2013974. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.022. (PubMed PMID: 35120736)","journal-title":"J Hepatol"},{"issue":"7","key":"11091_CR8","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","volume":"144","author":"R Moreau","year":"2013","unstructured":"Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426\u201337, 1437.e1-9. https:\/\/doi.org\/10.1053\/j.gastro.2013.02.042. (PubMed PMID: 23474284)","journal-title":"Gastroenterology"},{"issue":"5","key":"11091_CR9","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jhep.2020.11.019","volume":"74","author":"J Trebicka","year":"2021","unstructured":"Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, et al. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol. 2021;74(5):1097\u20131108. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.019. (PubMed PMID: 33227350)","journal-title":"J Hepatol"},{"key":"11091_CR10","unstructured":"The Australian Institute of Health and Welfare. Australian Burden of Disease Study 2024 [Internet]. Melbourne: AIHW; 2024. Report No. Available from: https:\/\/www.aihw.gov.au\/reports\/burden-of-disease\/australian-burden-of-disease-study-2024\/"},{"key":"11091_CR11","unstructured":"Majumdar A, Holmes J, Roberts SK, Bhat P, Mitchell T. The diagnosis and management of portal hypertension in cirrhosis: the GESA Consensus. Hepatol Commun. 2025; (Accepted In Press)."},{"key":"11091_CR12","unstructured":"Australian Bureau of Statistics. Causes of death, Australia [Internet]. Canberra: ABS; 2024. Report No. Available from: https:\/\/www.abs.gov.au\/statistics\/health\/causes-death\/causes-death-australia\/latest-release"},{"issue":"9","key":"11091_CR13","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1111\/jgh.15009","volume":"35","author":"LA Adams","year":"2020","unstructured":"Adams LA, Roberts SK, Strasser SI, Mahady SE, Powell E, Estes C, et al. Nonalcoholic fatty liver disease burden: Australia, 2019\u20132030. J Gastroenterol Hepatol. 2020;35(9):1628\u20131635. https:\/\/doi.org\/10.1111\/jgh.15009. (PubMed PMID: 32048317; PubMed Central PMCID: PMC7540570)","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"11091_CR14","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/imj.15962","volume":"53","author":"GC Lovett","year":"2023","unstructured":"Lovett GC, Ha P, Roberts AT, Bell S, Liew D, Pianko S, et al. Healthcare utilisation and costing for decompensated chronic liver disease hospitalisations at a Victorian network. Intern Med J. 2023;53(9):1581\u20131587. https:\/\/doi.org\/10.1111\/imj.15962","journal-title":"Intern Med J"},{"key":"11091_CR15","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jhep.2020.11.042","volume":"75","author":"P Jepsen","year":"2021","unstructured":"Jepsen P, Younossi ZM. The global burden of cirrhosis: a review of disability-adjusted life-years lost and unmet needs. J Hepatol. 2021;75:S3-13. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.042. (PubMed PMID: 34039490)","journal-title":"J Hepatol"},{"key":"11091_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.eclinm.2019.05.007","volume":"11","author":"EE Powell","year":"2019","unstructured":"Powell EE, Skoien R, Rahman T, Clark PJ, O\u2019Beirne J, Hartel G, et al. Increasing hospitalization rates for cirrhosis: overrepresentation of disadvantaged Australians. EClinicalMedicine. 2019;11:44\u201353. https:\/\/doi.org\/10.1016\/j.eclinm.2019.05.007. (PubMed PMID: 31317132; PubMed Central PMCID: PMC6610783)","journal-title":"EClinicalMedicine"},{"issue":"9","key":"11091_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.5694\/mja2.70036","volume":"223","author":"V Bhasker","year":"2025","unstructured":"Bhasker V, Fong JR, Clark PJ, Hartel GF, Skoien R, O\u2019Beirne J, et al. Cause-specific mortality among Queensland people with cirrhosis, by cirrhosis aetiology and decompensation status, 2007-22: a retrospective cohort study. Med J Aust. 2025;223(9):473\u2013483. https:\/\/doi.org\/10.5694\/mja2.70036. (PubMed PMID: 40931480; PubMed Central PMCID: PMC12579921)","journal-title":"Med J Aust"},{"issue":"8","key":"11091_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.5694\/mja2.52104","volume":"219","author":"J O\u2019Beirne","year":"2023","unstructured":"O\u2019Beirne J, Skoien R, Leggett BA, Hartel GF, Gordon LG, Powell EE, et al. Diabetes mellitus and the progression of non-alcoholic fatty liver disease to decompensated cirrhosis: a retrospective cohort study. Med J Aust. 2023;219(8):358\u2013365. https:\/\/doi.org\/10.5694\/mja2.52104. (PubMed PMID: 37749902)","journal-title":"Med J Aust"},{"issue":"8","key":"11091_CR19","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/jgh.16197","volume":"38","author":"JD Chetwood","year":"2023","unstructured":"Chetwood JD, Sabih AH, Chan K, Salimi S, Sheiban A, Lin E, et al. Epidemiology, characteristics, and outcomes of patients with acute-on-chronic liver failure in Australia. J Gastroenterol Hepatol. 2023;38(8):1325\u20131332. https:\/\/doi.org\/10.1111\/jgh.16197. (PubMed PMID: 37096760)","journal-title":"J Gastroenterol Hepatol"},{"key":"11091_CR20","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003744","author":"AW Jeffrey","year":"2025","unstructured":"Jeffrey AW, Majumdar A, Jeffrey G, Calzadilla-Bertot L, Wallace M, Mitchell T, et al. The portal hypertension decompensation score\u2014a validated predictive model of liver decompensation related to portal hypertension. Am J Gastroenterol. 2025. https:\/\/doi.org\/10.14309\/ajg.0000000000003744","journal-title":"Am J Gastroenterol."},{"issue":"2","key":"11091_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1053\/j.gastro.2013.04.005","volume":"145","author":"SK Asrani","year":"2013","unstructured":"Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145(2):375-382.e1-2. https:\/\/doi.org\/10.1053\/j.gastro.2013.04.005. (PubMed PMID: 23583430; PubMed Central PMCID: PMC3890240)","journal-title":"Gastroenterology"},{"issue":"2","key":"11091_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2023.04.021","volume":"79","author":"R Moreau","year":"2023","unstructured":"Moreau R, Tonon M, Krag A, Angeli P, Berenguer M, Berzigotti A, et al. EASL clinical practice guidelines on acute-on-chronic liver failure. J Hepatol. 2023;79(2):461\u2013491. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.021. (PubMed PMID: 37364789)","journal-title":"J Hepatol"},{"issue":"6","key":"11091_CR23","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.jhep.2020.12.003","volume":"74","author":"MA Abdallah","year":"2021","unstructured":"Abdallah MA, Kuo YF, Asrani S, Wong RJ, Ahmed A, Kwo P, et al. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality. J Hepatol. 2021;74(6):1355\u20131361. https:\/\/doi.org\/10.1016\/j.jhep.2020.12.003","journal-title":"J Hepatol"},{"issue":"10","key":"11091_CR24","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/apt.12721","volume":"39","author":"G D\u2019Amico","year":"2014","unstructured":"D\u2019Amico G, Pasta L, Morabito A, D\u2019Amico M, Caltagirone M, Malizia G, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39(10):1180\u20131193. https:\/\/doi.org\/10.1111\/apt.12721","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"11091_CR25","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/hep.23500","volume":"51","author":"P Jepsen","year":"2010","unstructured":"Jepsen P, Ott P, Andersen PK, S\u00f8rensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51(5):1675. https:\/\/doi.org\/10.1002\/hep.23500","journal-title":"Hepatology"},{"issue":"10258","key":"11091_CR26","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u20131222. https:\/\/doi.org\/10.1016\/S0140-6736(20)30925-9. (PubMed PMID: 33069326)","journal-title":"Lancet"},{"key":"11091_CR27","volume-title":"Australian burden of disease study: methods and supplementary material 2018","author":"The Australian Institute of Health and Welfare","year":"2018","unstructured":"The Australian Institute of Health and Welfare. Australian burden of disease study: methods and supplementary material 2018. Melbourne: AIHW; 2018"},{"issue":"3","key":"11091_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15861","volume":"45","author":"MS Schulz","year":"2025","unstructured":"Schulz MS, Angeli P, Trebicka J. Acute and non\u2010acute decompensation of liver cirrhosis (47\/130). Liver Int. 2025;45(3): e15861. https:\/\/doi.org\/10.1111\/liv.15861. (PubMed PMID: 38426268; PubMed Central PMCID: PMC11815624)","journal-title":"Liver Int"},{"issue":"4","key":"11091_CR29","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1097\/HEP.0000000000000460","volume":"78","author":"M Tonon","year":"2023","unstructured":"Tonon M, Balcar L, Semmler G, Calvino V, Scheiner B, Incicco S, et al. Etiological cure prevents further decompensation and mortality in patients with cirrhosis with ascites as the single first decompensating event. Hepatology. 2023;78(4):1149\u20131158. https:\/\/doi.org\/10.1097\/HEP.0000000000000460. (PubMed PMID: 37190823)","journal-title":"Hepatology"},{"issue":"1","key":"11091_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jhep.2024.12.017","volume":"83","author":"JI Fortea","year":"2025","unstructured":"Fortea JI, Alvarado-Tapias E, Simbrunner B, Ezcurra I, Hern\u00e1ndez-Gea V, Aracil C, et al. Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis. J Hepatol. 2025;83(1):70\u201380. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.017. (PubMed PMID: 39701300)","journal-title":"J Hepatol"},{"issue":"10138","key":"11091_CR31","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","volume":"391","author":"P Caraceni","year":"2018","unstructured":"Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391(10138):2417\u20132429. https:\/\/doi.org\/10.1016\/S0140-6736(18)30840-7. (PubMed PMID: 29861076)","journal-title":"Lancet"},{"key":"11091_CR32","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003589","author":"B Chapman","year":"2025","unstructured":"Chapman B, Sinclair M, Majumdar A, Yu C, Widdop J, Hoermann R, et al. Real-world experience of home continuous terlipressin infusion for complications of portal hypertension. Am J Gastroenterol. 2025. https:\/\/doi.org\/10.14309\/ajg.0000000000003589. (PubMed PMID: 40498117)","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"11091_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","volume":"152","author":"C Bureau","year":"2017","unstructured":"Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152(1):157\u2013163. https:\/\/doi.org\/10.1053\/j.gastro.2016.09.016. (PubMed PMID: 27663604)","journal-title":"Gastroenterology"},{"key":"11091_CR34","unstructured":"Gastroenterological Society of Australia (GESA). Clinical practice resources\u2014cirrhosis care bundle [Internet]. 2022 [cited 2025 Dec 8]. Available from: https:\/\/www.gesa.org.au\/resources\/clinical-practice-resources\/"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11091-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11091-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11091-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:41:11Z","timestamp":1787758871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11091-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["11091"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11091-7","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Leon Adams: On advisory board and received speaker honoraria from Novo Nordisc, CSL Behring; speaker honorarium from Dr Falk Pharma, Boehringer Ingelheim; consultancy fees from CSL Seqirus and grant support Novo Nordisk. John Chetwood: speaker fees from Dr Falk Pharma, Novartis, Takeda, Johnson & Johnson, and Eli Lilly. Ken Liu: speaker honorarium from CSL Behring. Avik Majumdar: advisory boards for CSL Behring, Ipsen, Gilead, Dr Falk Pharma; speaker honoraria from Norgine, Ipsen, CSL Behring. Michael Wallace: advisory board\/speaking honoraria for Roche, Bayer, Eisai, Sirtex and Ipsen.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patient data were de-identified, and ethics approval along with a waiver of patient consent was obtained through the Austin Health Human Research Ethics Committee (HREC\/23685\/Austin-2025).","order":2,"name":"Ethics","label":"Ethical approval and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}